Wall Street brokerages predict that ICU Medical, Incorporated (NASDAQ:ICUI) will announce sales of $321.05 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for ICU Medical’s earnings, with estimates ranging from $317.80 million to $324.30 million. ICU Medical reported sales of $372.03 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 13.7%. The business is expected to report its next quarterly earnings results after the market closes on Wednesday, May 8th.

According to Zacks, analysts expect that ICU Medical will report full year sales of $1.32 billion for the current fiscal year, with estimates ranging from $1.31 billion to $1.32 billion. For the next fiscal year, analysts expect that the company will post sales of $1.37 billion, with estimates ranging from $1.36 billion to $1.38 billion. Zacks’ sales averages are an average based on a survey of research firms that cover ICU Medical.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, February 28th. The medical instruments supplier reported $1.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.22. The firm had revenue of $340.38 million during the quarter, compared to the consensus estimate of $314.60 million. ICU Medical had a return on equity of 13.31% and a net margin of 2.06%.

Several analysts have commented on the company. Zacks Investment Research raised ICU Medical from a “hold” rating to a “buy” rating and set a $262.00 price objective for the company in a research note on Thursday, March 7th. BidaskClub downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 27th. TheStreet downgraded ICU Medical from a “b-” rating to a “c+” rating in a research note on Tuesday, March 19th. Finally, Raymond James reduced their price objective on ICU Medical from $315.00 to $300.00 and set a “strong-buy” rating for the company in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $281.00.

ICUI opened at $225.69 on Tuesday. The company has a market cap of $4.55 billion, a price-to-earnings ratio of 29.27 and a beta of 0.74. ICU Medical has a 52 week low of $210.94 and a 52 week high of $321.70.

In other news, Director Robert S. Swinney sold 229 shares of the stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $231.43, for a total transaction of $52,997.47. Following the completion of the transaction, the director now directly owns 18,076 shares of the company’s stock, valued at approximately $4,183,328.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 5,277 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $232.31, for a total value of $1,225,899.87. Following the transaction, the vice president now directly owns 13,167 shares of the company’s stock, valued at $3,058,825.77. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,470 shares of company stock valued at $1,985,710. Company insiders own 11.40% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Advisory Services Network LLC raised its stake in shares of ICU Medical by 475.0% during the 4th quarter. Advisory Services Network LLC now owns 115 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 95 shares in the last quarter. We Are One Seven LLC purchased a new position in shares of ICU Medical during the 4th quarter worth approximately $32,000. Berman Capital Advisors LLC acquired a new stake in shares of ICU Medical in the 4th quarter worth approximately $33,000. CX Institutional acquired a new stake in shares of ICU Medical in the 1st quarter worth approximately $34,000. Finally, Financial Gravity Companies Inc. acquired a new stake in shares of ICU Medical in the 4th quarter worth approximately $45,000. 92.78% of the stock is owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Featured Story: The Structure of a Futures Contract

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.